Metabolic Brain Disease

, Volume 34, Issue 5, pp 1365–1374 | Cite as

Amyloid Beta 25–35 induces blood-brain barrier disruption in vitro

  • Elvis CuevasEmail author
  • Hector Rosas-Hernandez
  • Susan M. Burks
  • Manuel A. Ramirez-Lee
  • Aida Guzman
  • Syed Z. Imam
  • Syed F. Ali
  • Sumit Sarkar
Original Article


The amyloid β-peptide (Aβ) is transported across the blood-brain barrier (BBB) by binding with the receptor for advanced glycation end products (RAGE). Previously, we demonstrated that the Aβ fraction 25–35 (Aβ25–35) increases RAGE expression in the rat hippocampus, likely contributing to its neurotoxic effects. However, it is still debated if the interaction of Aβ with RAGE compromises the BBB function in Alzheimer’ disease (AD). Here, we evaluated the effects of Aβ25–35 in an established in vitro model of the BBB. Rat brain microvascular endothelial cells (rBMVECs) were treated with 20 μM active Aβ25–35 or the inactive Aβ35–25 (control), for 24 h. Exposure to Aβ25–35 significantly decreased cell viability, increased cellular necrosis, and increased the production of reactive oxygen species (ROS), which triggered a decrease in the enzyme glutathione peroxidase when compared to the control condition. Aβ25–35 also increased BBB permeability by altering the expression of tight junction proteins (decreasing zonula occludens-1 and increasing occludin). Aβ25–35 induced monolayer disruption and cellular disarrangement of the BBB, with RAGE being highly expressed in the zones of disarrangement. Together, these data suggest that Aβ25–35-induces toxicity by compromising the functionality and integrity of the BBB in vitro.

Graphical abstract

25-35 induces BBB dysfunction in vitro, wich is likely mediated by OS and ultimately leads to disruption of BBB integrity and cell death


Amyloid β fraction 25–35 Blood-brain barrier Oxidative stress Permeability RAGE Zonula occludens 1 



These studies were supported by FDA/NCTR, E0763101, and postdoctoral fellowships from the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the FDA (to E. Cuevas). The authors are grateful to John Talpos for support in preparing this manuscript.

The views and the information in this article is solely the responsibility of the authors and is not a formal dissemination of information by the U.S. Food and Drug Administration and does not represent agency position or policy.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.


  1. Alzheimer's A (2016) 2016 Alzheimer's disease facts and figures. Alzheimers Dement 12(4):459–509CrossRefGoogle Scholar
  2. Bednarczyk J, Lukasiuk K (2011) Tight junctions in neurological diseases. Acta Neurobiol Exp (Wars) 71(4):393–408Google Scholar
  3. Bernal-Mondragon C, Rivas-Arancibia S, Kendrick KM, Guevara-Guzman R (2013) Estradiol prevents olfactory dysfunction induced by A-beta 25-35 injection in hippocampus. BMC Neurosci 14:104CrossRefGoogle Scholar
  4. Blasig IE, Bellmann C, Cording J, Del Vecchio G, Zwanziger D, Huber O, Haseloff RF (2011) Occludin protein family: oxidative stress and reducing conditions. Antioxid Redox Signal 15(5):1195–1219CrossRefGoogle Scholar
  5. Butterfield DA, Kanski J (2002) Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide 1-42. Peptides 23(7):1299–1309CrossRefGoogle Scholar
  6. Carrano A, Hoozemans JJ, van der Vies SM, Rozemuller AJ, van Horssen J, de Vries HE (2011) Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 15(5):1167–1178CrossRefGoogle Scholar
  7. Chaney MO, Stine WB, Kokjohn TA, Kuo YM, Esh C, Rahman A, Luehrs DC, Schmidt AM, Stern D, Yan SD, Roher AE (2005) RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim Biophys Acta 1741(1–2):199–205CrossRefGoogle Scholar
  8. Cuevas E, Limon D, Perez-Severiano F, Diaz A, Ortega L, Zenteno E, Guevara J (2009) Antioxidant effects of Epicatechin on the hippocampal toxicity caused by amyloid-beta 25-35 in rats. Eur J Pharmacol 616(1–3):122–127CrossRefGoogle Scholar
  9. Cuevas E, Lantz S, Newport G, Divine B, Wu Q, Paule MG, Tobon-Velasco JC, Ali SF, Santamaria A (2010) On the early toxic effect of quinolinic acid: involvement of RAGE. Neurosci Lett 474(2):74–78CrossRefGoogle Scholar
  10. Cuevas E, Lantz SM, Tobon-Velasco JC, Newport GD, Wu Q, Virmani A, Ali SF, Santamaria A (2011) On the in vivo early toxic properties of A-beta 25-35 peptide in the rat hippocampus: involvement of the receptor-for-advanced glycation-end-products and changes in gene expression. Neurotoxicol Teratol 33(2):288–296CrossRefGoogle Scholar
  11. Deane RJ (2012) Is RAGE still a therapeutic target for Alzheimer's disease? Future Med Chem 4(7):915–925CrossRefGoogle Scholar
  12. Deane R, Zlokovic BV (2007) Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 4(2):191–197CrossRefGoogle Scholar
  13. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9(7):907–913CrossRefGoogle Scholar
  14. Deane R, Wu Z, Zlokovic BV (2004) RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35(11 Suppl 1):2628–2631CrossRefGoogle Scholar
  15. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S, Paquette N, Deane RJ, Thiyagarajan M, Zarcone T, Fritz G, Friedman AE, Miller BL, Zlokovic BV (2012) A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122(4):1377–1392CrossRefGoogle Scholar
  16. Denizot F, Lang R (1986) Rapid colorimetric assay for cell-growth and survival - modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89(2):271–277CrossRefGoogle Scholar
  17. Do TM, Dodacki A, Alata W, Calon F, Nicolic S, Scherrmann JM, Farinotti R, Bourasset F (2016) Age-dependent regulation of the blood-brain barrier influx/efflux equilibrium of amyloid-beta peptide in a mouse model of Alzheimer's disease (3xTg-AD). J Alzheimers Dis 49(2):287–300CrossRefGoogle Scholar
  18. Donahue JE, Flaherty SL, Johanson CE, Duncan JA 3rd, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG (2006) RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 112(4):405–415CrossRefGoogle Scholar
  19. Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM (1998) The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem 273(45):29745–29753CrossRefGoogle Scholar
  20. Frozza RL, Horn AP, Hoppe JB, Simao F, Gerhardt D, Comiran RA, Salbego CG (2009) A comparative study of beta-amyloid peptides Abeta1-42 and Abeta25-35 toxicity in organotypic hippocampal slice cultures. Neurochem Res 34(2):295–303CrossRefGoogle Scholar
  21. Gheorghiu M, Enciu AM, Popescu BO, Gheorghiu E (2014) Functional and molecular characterization of the effect of amyloid-beta42 on an in vitro epithelial barrier model. J Alzheimers Dis 38(4):787–798CrossRefGoogle Scholar
  22. Gospodarska E, Kupniewska-Kozak A, Goch G, Dadlez M (2011) Binding studies of truncated variants of the Abeta peptide to the V-domain of the RAGE receptor reveal Abeta residues responsible for binding. Biochim Biophys Acta 1814(5):592–609CrossRefGoogle Scholar
  23. Guimaraes CC, Oliveira DD, Valdevite M, Saltoratto AL, Pereira SI, Franca Sde C, Pereira AM, Pereira PS (2015) The glycosylated flavonoids vitexin, isovitexin, and quercetrin isolated from Serjania erecta Radlk (Sapindaceae) leaves protect PC12 cells against amyloid-beta25-35 peptide-induced toxicity. Food Chem Toxicol 86:88–94CrossRefGoogle Scholar
  24. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12(10):383–388CrossRefGoogle Scholar
  25. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580):353–356CrossRefGoogle Scholar
  26. Kook SY, Hong HS, Moon M, Ha CM, Chang S, Mook-Jung I (2012) Abeta(1)(−)(4)(2)-RAGE interaction disrupts tight junctions of the blood-brain barrier via ca(2)(+)-calcineurin signaling. J Neurosci 32(26):8845–8854CrossRefGoogle Scholar
  27. Kubo T, Nishimura S, Kumagae Y, Kaneko I (2002) In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res 70:474–483Google Scholar
  28. Liu R, Gao M, Qiang GF, Zhang TT, Lan X, Ying J, Du GH (2009) The anti-amnesic effects of luteolin against amyloid beta(25-35) peptide-induced toxicity in mice involve the protection of neurovascular unit. Neuroscience 162(4):1232–1243CrossRefGoogle Scholar
  29. Liu T, Liu WH, Zhao JS, Meng FZ, Wang H (2017a) Lutein protects against beta-amyloid peptide-induced oxidative stress in cerebrovascular endothelial cells through modulation of Nrf-2 and NF-kappab. Cell Biol Toxicol 33(1):57–67CrossRefGoogle Scholar
  30. Liu XY, Zhang LJ, Chen Z, Liu LB (2017b) The PTEN inhibitor bpV(pic) promotes neuroprotection against amyloid beta-peptide (25-35)-induced oxidative stress and neurotoxicity. Neurol Res 39(8):758–765CrossRefGoogle Scholar
  31. Lochhead JJ, McCaffrey G, Quigley CE, Finch J, DeMarco KM, Nametz N, Davis TP (2010) Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. J Cereb Blood Flow Metab 30(9):1625–1636CrossRefGoogle Scholar
  32. Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, Yan SD, Stern D, Schmidt AM, Frangione B, Zlokovic BV (1998) Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest 102(4):734–743CrossRefGoogle Scholar
  33. Mark KS, Davis TP (2002) Cerebral microvascular changes in permeability and tight junctions induced by hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol 282(4):H1485–H1494CrossRefGoogle Scholar
  34. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330(6012):1774CrossRefGoogle Scholar
  35. Millucci L, Ghezzi L, Bernardini G, Santucci A (2010) Conformations and biological activities of amyloid beta peptide 25-35. Curr Protein Pept Sci 11:54–67Google Scholar
  36. Paik S, Somvanshi RK, Kumar U (2018) Somatostatin maintains permeability and integrity of blood-brain barrier in beta-amyloid induced toxicity. Mol NeurobiolGoogle Scholar
  37. Park S, Kim DS, Kang S, Moon NR (2013) Beta-amyloid-induced cognitive dysfunction impairs glucose homeostasis by increasing insulin resistance and decreasing beta-cell mass in non-diabetic and diabetic rats. Metabolism 62(12):1749–1760CrossRefGoogle Scholar
  38. Perez-Severiano F, Salvatierra-Sanchez R, Rodriguez-Perez M, Cuevas-Martinez EY, Guevara J, Limon D, Maldonado PD, Medina-Campos ON, Pedraza-Chaverri J, Santamaria A (2004) S-allylcysteine prevents amyloid-beta peptide-induced oxidative stress in rat hippocampus and ameliorates learning deficits. Eur J Pharmacol 489(3):197–202CrossRefGoogle Scholar
  39. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW (1993) Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13(4):1676–1687CrossRefGoogle Scholar
  40. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW (1995) Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 64(1):253–265CrossRefGoogle Scholar
  41. Provias J, Jeynes B (2014) The role of the blood-brain barrier in the pathogenesis of senile plaques in Alzheimer's disease. Int J Alzheimers Dis 2014:191863Google Scholar
  42. Qosa H, LeVine H 3rd, Keller JN, Kaddoumi A (2014) Mixed oligomers and monomeric amyloid-beta disrupts endothelial cells integrity and reduces monomeric amyloid-beta transport across hCMEC/D3 cell line as an in vitro blood-brain barrier model. Biochim Biophys Acta 1842(9):1806–1815CrossRefGoogle Scholar
  43. Rosas-Hernandez H, Cuevas E, Lantz SM, Hamilton WR, Ramirez-Lee MA, Ali SF, Gonzalez C (2013a) Prolactin and blood-brain barrier permeability. Curr Neurovasc Res 10(4):278–286CrossRefGoogle Scholar
  44. Rosas-Hernandez H, Cuevas E, Lantz-McPeak SM, Ali SF, Gonzalez C (2013b) Prolactin protects against the methamphetamine-induced cerebral vascular toxicity. Curr Neurovasc Res 10(4):346–355CrossRefGoogle Scholar
  45. Rosas-Hernandez H, Cuevas E, Escudero-Lourdes C, Lantz SM, Sturdivant NM, Imam SZ, Sarkar S, Slikker W Jr, Paule MG, Balachandran K, Ali SF (2018a) Characterization of uniaxial high-speed stretch as an in vitro model of mild traumatic brain injury on the blood-brain barrier. Neurosci Lett 672:123–129CrossRefGoogle Scholar
  46. Rosas-Hernandez H, Cuevas E, Lantz SM, Paule MG, Ali SF (2018b) Isolation and culture of brain microvascular endothelial cells for in vitro blood-brain barrier studies. Methods Mol Biol 1727:315–331CrossRefGoogle Scholar
  47. Self RL, Smith KJ, Mulholland PJ, Prendergast MA (2005) Ethanol exposure and withdrawal sensitizes the rat hippocampal CA1 pyramidal cell region to beta-amyloid (25-35)-induced cytotoxicity: NMDA receptor involvement. Alcohol Clin Exp Res 29(11):2063–2069CrossRefGoogle Scholar
  48. Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8:595–608CrossRefGoogle Scholar
  49. Steinerman JR, Irizarry M, Scarmeas N, Raju S, Brandt J, Albert M, Blacker D, Hyman B, Stern Y (2008) Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch Neurol 65(7):906–912CrossRefGoogle Scholar
  50. Stepanichev MY, Moiseeva YV, Lazareva NA, Onufriev MV, Gulyaeva NV (2010) Changes in cell proliferation in the subventricular zone of the brain in adult rats given beta-amyloid peptide (25-35). Neurosci Behav Physiol 40(2):123–126CrossRefGoogle Scholar
  51. Strazielle N, Ghersi-Egea JF, Ghiso J, Dehouck MP, Frangione B, Patlak C, Fenstermacher J, Gorevic P (2000) In vitro evidence that beta-amyloid peptide 1-40 diffuses across the blood-brain barrier and affects its permeability. J Neuropathol Exp Neurol 59(1):29–38CrossRefGoogle Scholar
  52. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology 58(12):1791–1800CrossRefGoogle Scholar
  53. Uttara B, Singh AV, Zamboni P, Mahajan RT (2009) Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 7(1):65–74CrossRefGoogle Scholar
  54. Wan WB, Cao L, Liu LM, Kalionis B, Chen C, Tai XT, Li YM, Xia SJ (2014a) EGb761 provides a protective effect against Abeta1-42 oligomer-induced cell damage and blood-brain barrier disruption in an in vitro bEnd.3 endothelial model. PLoS One 9(11):e113126CrossRefGoogle Scholar
  55. Wan W, Chen H, Li Y (2014b) The potential mechanisms of Abeta-receptor for advanced glycation end-products interaction disrupting tight junctions of the blood-brain barrier in Alzheimer's disease. Int J Neurosci 124(2):75–81CrossRefGoogle Scholar
  56. Wan W, Cao L, Liu L, Zhang C, Kalionis B, Tai X, Li Y, Xia S (2015) Abeta(1-42) oligomer-induced leakage in an in vitro blood-brain barrier model is associated with up-regulation of RAGE and metalloproteinases, and down-regulation of tight junction scaffold proteins. J Neurochem 134(2):382–393CrossRefGoogle Scholar
  57. Wang H, Joseph JA (1999) Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic Biol Med 27(5–6):612–616CrossRefGoogle Scholar
  58. Wang H, Chen F, Du YF, Long Y, Reed MN, Hu M, Suppiramaniam V, Hong H, Tang SS (2018) Targeted inhibition of RAGE reduces amyloid-beta influx across the blood-brain barrier and improves cognitive deficits in db/db mice. Neuropharmacology 131:143–153CrossRefGoogle Scholar
  59. Watson PM, Anderson JM, Vanltallie CM, Doctrow SR (1991) The tight-junction-specific protein ZO-1 is a component of the human and rat blood-brain barriers. Neurosci Lett 129(1):6–10CrossRefGoogle Scholar
  60. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO (2008) Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 18(2):253–266CrossRefGoogle Scholar
  61. Xie J, Reverdatto S, Frolov A, Hoffmann R, Burz DS, Shekhtman A (2008) Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem 283(40):27255–27269CrossRefGoogle Scholar
  62. Xu P, Wang H, Li Z, Yang Z (2016) Triptolide attenuated injury via inhibiting oxidative stress in amyloid-Beta25-35-treated differentiated PC12 cells. Life Sci 145:19–26CrossRefGoogle Scholar
  63. Yan SD, Chen X, Fu J, Chen M, Godman G, Stern D, Schmidt AM (1996a) RAGE: a receptor upregulated in Alzheimer's disease on neurons, microglia, and cerebrovascular endothelium that binds amyloid-beta peptide and mediates induction of oxidant stress. Neurology 46(2):23005–23005Google Scholar
  64. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996b) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382(6593):685–691CrossRefGoogle Scholar
  65. Yankner BA, Duffy LK, Kirschner DA (1990) Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250(4978):279–282CrossRefGoogle Scholar
  66. Zhang JX, Xing JG, Wang LL, Jiang HL, Guo SL, Liu R (2017) Luteolin inhibits fibrillary beta-Amyloid1-40-induced inflammation in a human blood-brain barrier model by suppressing the p38 MAPK-mediated NF-kappaB signaling pathways. Molecules 22(3)Google Scholar
  67. Zheng X, Xie Z, Zhu Z, Liu Z, Wang Y, Wei L, Yang H, Yang H, Liu Y, Bi J (2014) Methyllycaconitine alleviates amyloid-beta peptides-induced cytotoxicity in SH-SY5Y cells. PLoS One 9(10):e111536CrossRefGoogle Scholar
  68. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12(12):723–738CrossRefGoogle Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply  2019

Authors and Affiliations

  • Elvis Cuevas
    • 1
    Email author
  • Hector Rosas-Hernandez
    • 1
  • Susan M. Burks
    • 1
  • Manuel A. Ramirez-Lee
    • 1
  • Aida Guzman
    • 2
  • Syed Z. Imam
    • 1
  • Syed F. Ali
    • 1
  • Sumit Sarkar
    • 1
  1. 1.Division of Neurotoxicology, National Center for Toxicological Research/U.S. Food and Drug AdministrationJeffersonUSA
  2. 2.Escuela Nacional Preparatoria-UNAMMexicoMexico

Personalised recommendations